

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C12N 15/82, 15/55, 9/22 C12N 15/31, A01N 63/02 C12N 5/10, A01H 5/00, 1/02</p>	<p>A1</p>	<p>(11) International Publication Number: WO 93/08291 (43) International Publication Date: 29 April 1993 (29.04.93)</p>
<p>(21) International Application Number: PCT/EP92/02420 (22) International Filing Date: 15 October 1992 (15.10.92) (30) Priority data: 91402767.7 16 October 1991 (16.10.91) EP (34) Countries for which the regional or international application was filed: FR et al. (71) Applicant (for all designated States except US): PLANT GENETIC SYSTEMS, N.V. [BE/BE]; Kolonel Bourgstraat 106, B-1040 Brussels (BE). (72) Inventors; and (75) Inventors/Applicants (for US only) : NAZAROV, Victor [CS/US]; Public Health Service, National Institutes of Health, National Cancer Institute, Department of Health & Human Services, Bldg.37, Rm1B26, Bethesda, MD 20892 (US). BOTTERMAN, Johan [BE/BE]; Plant Genetic Systems N.V., Plateauststraat 22, B-9000 Gent (BE). STANSSENS, Patrick [BE/BE]; Permekelaan 48, B-9830 Saint-Martens-Latem (BE). SEVCIK, Jozef [CS/CS]; Pupavova 1, 841 04 Bratislava (CS).</p>		<p>(74) Agents: GUTMANN, Ernest et al.; Ernest Gutmann - Yves Plasseraud S.A., 67, boulevard Haussmann, F-75008 Paris (FR). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: A NOVEL RIBONUCLEASE AND ITS INHIBITOR</p> <p>(57) Abstract</p> <p>Novel RNase DNAs and their use in the disruption of the normal functioning, metabolism or development of cells of selected tissues or organs of eukaryotic organisms, particularly plants, transformed with the RNase DNAs. Also novel RNase-inhibitor DNAs and their use in restoring normal functioning, metabolism and development of cells disrupted by expression of the RNase DNAs.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

A NOVEL RIBONUCLEASE AND ITS INHIBITOR

This invention relates to a novel ribonuclease, containing only one disulfide bridge, and a novel inhibitor for the ribonuclease, both of which are obtainable from Streptomyces aureofaciens strain RO8/26, deposited at the DSM under accession no. 6691 on August 27, 1991.

This invention also relates to DNA coding for the novel ribonuclease and ribonuclease-inhibitor.

This invention further relates to the use of a first chimaeric gene comprising a DNA coding for a ribonuclease such as the novel ribonuclease of this invention, under the control of a promoter sequence adapted to provide expression of the ribonuclease-encoding DNA only in cells of selected organs and/or tissues of eucaryotic organisms, particularly plants, transformed with the chimaeric gene, so as to disrupt the metabolism selectively of such cells.

This invention still further relates to the use of a second chimaeric gene comprising a DNA coding for an ribonuclease-inhibitor such as the novel ribonuclease-inhibitor of this invention, under the control of a promoter sequence adapted to provide expression of the DNA encoding the ribonuclease-inhibitor at least in cells of eucaryotic organisms where the first chimaeric gene is expressed, so as to neutralize or inactivate the activity of the ribonuclease expressed in such cells.

This invention also relates to eucaryotic cells and organisms, particularly plants and their cells and seeds, transformed with the first and/or second chimaeric genes.

Background of the Invention

Ribonucleases are secreted by many procaryotic and eucaryotic sources. One example of an eucaryotic ribonuclease is Rnase T1 which is produced by the fungus Aspergillus

oryzae. A gene coding for this enzyme has been synthesized and expressed in Escherichia coli (Quaas et al (1988) Eur. J. Biochem. 173:617). Examples of secreted procaryotic ribonucleases include Rnase Sa from Streptomyces aureofaciens Type BMK and barnase from Bacillus amyloliquefaciens. The amino acid sequence of Rnase Sa has been determined (Shlyapnikov et al (1986) FEBS Letters 209:335) while the gene coding for barnase has been isolated from B. amyloliquefaciens (see Hartley (1989) TIBS 14:450 for a review).

It is also known that many organisms that secrete ribonucleases will also produce specific intracellular inhibitors for such ribonucleases. Presumably, the inhibitor serves as a defense against the toxic effects of intracellular ribonuclease activity. One example of such an inhibitor is barstar which is produced by B. amyloliquefaciens and forms a one-to-one noncovalent complex with barnase. The barstar gene has also been isolated (Hartley (1989) TIBS 14:450). An inhibitor for Rnase Sa from S. aureofaciens has also been isolated and characterized (Mucha et al (1983a) Biologia 38:1177; Mucha et al (1983b) Biologia 38:1185), but up to now, the corresponding gene has not been isolated.

Recently, the coding sequences of Rnase T1 and barnase have been placed under the control of a tapetum specific promoter and the resulting chimaeric genes have been used for the transformation of various species of plants such as Brassica napus. The

intracellular expression of these ribonucleases was limited to the tapetum cell layer in the anthers of the transformed plants, and the plants were shown to be male sterile (European patent publication ("EP") 344 029; Mariani et al (1990) Nature 347:737).

A chimaeric gene consisting of the barstar gene under the control of the same tapetum specific promoter has also been used to transform plants. Crossing of male-sterile oilseed rape plants containing the chimaeric barnase gene with oilseed rape plants containing the chimaeric barstar gene resulted in progeny with fully restored fertility, proving that the barstar protein could inhibit the ribonuclease activity of barnase when genes encoding barnase and barstar are co-expressed in tapetum cells (EP 412 911; Mariani et al (1991) Proceedings of the CCIRC Rapeseed Congress, July 9-11, 1991, Saskatoon, Canada; Mariani et al (1992) Nature 357:384).

Summary of the Invention

The present invention provides an improvement in known methods to disrupt significantly the normal metabolism, functioning and/or development of selected cells, especially the cells of one or more selected tissues and/or one or more selected organs ("target cells"), of a eucaryotic organism, preferably a plant, by providing in each cell of the organism, preferably in its nuclear genome, a first chimaeric gene comprising in the same transcriptional unit:

a first DNA sequence (a "RNase DNA"), preferably a RNase DNA from S. aureofaciens (a "sarnase DNA"), particularly a sarnase DNA from S. aureofaciens strain R08/26 (a "R08/26 sarnase

DNA"); the RNase DNA coding for a protein (a "RNase") which has ribonuclease activity and which contains only one intramolecular disulfide bridge; the RNase preferably being an RNase from S. aureofaciens (a "sarnase"), particularly a sarnase from S. aureofaciens strain R08/26 (a "R08/26 sarnase"), quite particularly the mature R08/26 sarnase of SEQ ID no. 1;

a first promoter fused to the upstream (5') end of the RNase DNA and capable of directing expression of the RNase DNA substantially only in the target cells of the organism; the RNase DNA being under the control of the first promoter; and

suitable transcription termination signals, including a polyadenylation signal, fused to the downstream (3') end of the RNase DNA.

The preferred target cells are: cells of tissue of male or female reproductive organs, seeds or embryos of plants, preferably anther, pollen or filament cells, particularly anther epidermal cells and/or tapetum cells, or style, stigma, ovule, septum, seed coat, endosperm, embryo axis and/or embryo cotyledon cells, whereby expression of the first chimaeric gene of this invention renders the plants male or female-sterile; and cells of plant tissue which has been invaded by a pathogenic organism such as a nematode, whereby expression of the first chimaeric gene of this invention protects the plant tissue from further damage by the pathogenic organism.

The present invention also provides an improvement in known methods to prevent or diminish

the significant disruption of the normal metabolism, functioning or development of the target cells of a eucaryotic organism, preferably a plant, containing the first chimaeric gene in each of its cells, by providing in each of its cells, preferably in its nuclear genome, a second chimaeric gene comprising in the same transcriptional unit:

a second DNA sequence (a "RNase-inhibitor DNA"), preferably a RNase-inhibitor DNA from S. aureofaciens (a "sarstar DNA"), particularly a sarstar DNA from S. aureofaciens strain R08/26 (a "R08/26 sarstar DNA"); the RNase-inhibitor DNA coding for a protein (a "RNase-inhibitor") which can inhibit the RNase activity of the RNase; the RNase-inhibitor preferably being a RNase-inhibitor from S. aureofaciens (a "sarstar"), particularly a sarstar from S. aureofaciens strain R08/26 (a "R08/26 sarstar");

a second promoter fused to the upstream end of the RNase-inhibitor DNA and capable of directing the expression of the RNase-inhibitor DNA in at least the target cells; the RNase-inhibitor DNA being under the control of the second promoter; and

suitable transcription termination signals, including a polyadenylation signal, fused to the downstream end of the RNase-inhibitor DNA.

In eucaryotic organisms, particularly plants, expression in the same cells of both the first and second chimaeric genes and their respective RNase DNA under the control of the first promoter and RNase-inhibitor DNA under the control of the second promoter can be especially useful. For instance, the

progeny of two parents, the cells of one parent containing the RNase DNA under the control of a first promoter which is only active in male reproductive organs and the cells of the other parent containing the RNase-inhibitor DNA under the control of a second promoter which is active in the same cells of the male reproductive organs as the first promoter, will have restored fertility. Under appropriate conditions, this effect can be used in the production of hybrid seed. Hence, the present invention further provides a cell (a "transformed cell") of an eucaryotic organism, particularly a plant, comprising the first chimaeric gene and/or the second chimaeric gene, especially as an insert in the genomic DNA of the cell; and eucaryotic organisms, particularly plants as well as plant cell cultures and seeds, consisting of such transformed cells.

The present invention still further provides: the S. aureofaciens strain R08/26 which was deposited at the DSM under accession number 6691; the R08/26 sarnase DNA, particularly the R08/26 sarnase DNA of SEQ ID no. 1; the R08/26 sarstar DNA; the R08/26 sarnase, particularly the mature R08/26 sarnase with the amino acid sequence of SEQ ID no. 1; the R08/26 sarstar; and the first and second chimaeric genes.

Brief Description of the Drawings and the Sequences

In the following description of the invention and the examples, reference will be made to the following figures and sequences:

FIGURES

Figure 1: Restriction map of 2.2 kb DNA fragment of Streptomyces aureofaciens strain R08/26 (DSM 6691) containing the R08/26 sarnase

DNA of SEQ ID no. 1. The restriction sites under the line are important in the subcloning of the R08/26 sarnase DNA. The thick bar indicates the region whose sequence is given in SEQ ID no. 1.

Figure 2: Schematic representation of plasmid pTE4 (example 3). The most important features and restriction sites are shown. The numbers between brackets refer to cleavage sites in the sequence which is given in SEQ ID no. 3.

SEQUENCE LISTING

SEQ ID no. 1: nucleotide sequence comprising the novel R08/26 sarnase DNA from Streptomyces aureofaciens R08/26 (DSM 6691) and the corresponding amino acid sequence of the novel encoded sarnase.

SEQ ID no. 2: Nucleotide sequence of pMac5-19 (pMa5-19 and pMc5-19).

SEQ ID no. 3: Nucleotide sequence of pTE4 in Figure 2.

Detailed Description of the Invention

The Streptomyces aureofaciens strain R08/26 of this invention was isolated by conventional means and deposited at the DSM under accession number 6691. This strain is characterized in that it secretes a novel sarnase-type ribonuclease. The cells of this strain are protected against the toxic effect of its sarnase by the intracellular expression of a novel sarstar-type ribonuclease-inhibitor. DNAs coding for the sarnase and sarstar of S. aureofaciens R08/26 can

be isolated from this strain in a conventional manner. Equivalent sarnase DNAs and sarstar DNAs can be isolated from other strains of S. aureofaciens which are similar to S. aureofaciens R08/26 and which produce sarnases with only one disulfide bridge and corresponding inhibitory sarstars, such as S. aureofaciens Type BMK.

The RNase DNAs of this invention, coding for the RNases of this invention, can be isolated in a conventional manner. For example, the sarnase DNAs of this invention, coding for sarnases, can be obtained from S. aureofaciens strains and the like by conventional procedures, for instance as described in Example 1. For example, screening of a DNA library of total DNA of an S. aureofaciens strain can be carried out with an oligonucleotide corresponding to a sarnase which can be isolated from a S. aureofaciens, such as RNase Sa from S. aureofaciens type BMK (Shlyapnikov et al, supra), R08/26 sarnase from S. aureofaciens R08/26 having the sequence of SEQ ID no. 1, or an equivalent of RNase SA or R08/26 sarnase having substantially the same ribonuclease properties, particularly the capacity of being inhibited by a sarstar, such as the R08/26 sarstar.

A comparison of the expression and secretion in E.coli of RNase T1, which has two disulfide bridges, of a sarnase of this invention, which has only one disulfide bridge, and of barnase, which has no disulfide bridges, indicates that the sarnase has an intracellular toxicity (as measured by the growth of the bacterial culture) which is between that of RNase T1 and barnase, i.e., an intracellular toxicity greater than that of RNase T1 but less than that of barnase (see Example 2). Since disulfide bridges are formed with great difficulty in an intracellular

environment and since proper disulfide bridge formation appears to be required for a protein to have ribonuclease activity, it is believed that the number of disulfide bridges is an important determining factor in the intracellular activity of a ribonuclease. In this regard, disulfide bridges are formed with difficulty in the cytoplasm of eucaryotic cells, such as plant cells, and proteins need to be translocated to the endoplasmic reticulum in order for disulfide bridges to be formed.

The RNase DNAs, particularly the sarnase DNAs, of this invention can provide an improvement in known processes for disrupting the otherwise normal metabolism, functioning or development of selected cells of eucaryotic organisms, particularly plants.

For instance, plants can be transformed with the first chimaeric gene of this invention, comprising an RNase DNA under the control of a first promoter which has a high specificity for cells of a specific tissue in male or female reproductive organs (i.e., for target cells of the plant). The resulting transgenic plants have dysfunctional male or female reproductive organs and are male sterile or female sterile due to the selective disruption of normal metabolism, functioning or development in the target cells. The use of DNAs coding for such first chimaeric genes and their RNases and first promoters for providing male- or female-sterility in plants has been extensively described in EP 344 029 and EP 412 006 which are incorporated herein by reference.

Plants can also be transformed with the first chimaeric gene of this invention comprising a RNase DNA under the control of a first promoter which is nematode-induced, i.e., a promoter whose action in controlling transcription of a DNA sequence is

induced (e.g., stimulated) by infection of the plant by nematodes and preferably is induced selectively in cells of the plant's fixed feeding sites (e.g., giant cells, syncytia, nurse cells, and galls). The resulting transgenic plants will be resistant to nematode infections because of the plants' nematode induced breakdown of their fixed feeding sites which are essential for the survival of nematodes.

Preferably, the RNase DNAs, preferably sarnase DNAs, of this invention in the first chimaeric gene produce their encoded RNases, preferably sarnases, selectively in transformed target cells of an organism such as a plant so as to disrupt totally the cells' metabolism and thereby result in, for example, complete male- or female-sterility or nematode-resistance of the transformed plant. However in accordance with this invention, even if such RNases are also expressed to a significantly lesser degree in non-target cells of, for example, a plant (as a result of a relatively less selective first promoter in the first chimaeric gene), the RNases do not disrupt the metabolism, functioning or development of cells in other parts of the plant to an extent which could affect significantly the development or general agronomic performance of the plant.

The RNase-inhibitor DNAs of this invention, coding for the RNase-inhibitors of this invention, can also be isolated in a conventional manner. For example, the sarstar DNAs of this invention, coding for the sarstars, can be isolated from S. aureofaciens strains and the like by conventional procedures. For example, a sarstar can be purified from a bacterial strain according to the procedures described by Mucha et al (1983a) *Biologia* 38:1177, and its complete or N-terminal amino acid sequence

can be determined. The gene coding for this sarstar can then be isolated from the strain as exemplified in Example 5. In this regard, an oligonucleotide corresponding to a characteristic part of the obtained amino acid sequence can be used to screen a bank of DNA fragments, obtained by digesting DNA of the strain with an appropriate restriction enzyme and cloned in a suitable vector in a suitable bacterial host such as E. coli. Positive clones can then be further analyzed, e.g., by sequencing. Alternatively, the DNA can be isolated directly by means of positive selection as exemplified in Examples 3 and 4. In this regard, DNA fragments of the strain can be cloned in a suitable bacterial host, such as E. coli or a Streptomyces strain that already contains the sarnase gene under the control of an inducible promoter (such as the tac promoter). Upon induction the cloned DNA fragments of surviving colonies can be further analyzed (e.g., by means of sequencing).

In accordance with this invention, the RNase-inhibitor DNAs coding for specific inhibitors, preferably the sarstars, particularly R08/26 sarstar, of the RNases, preferably the sarnases, particularly R08/26 sarnase, can be used to inhibit the activity of the specific corresponding RNases. For instance, plants can be transformed with the second chimaeric gene of this invention comprising a RNase-inhibitor DNA under the control of a second promoter which is active at least in cells of the same tissues of the male or female reproductive organs of the resulting restorer plants where the corresponding RNase is expressed in male- or female-sterile plants of the same species. Appropriate crossing of such restorer plants and sterile plants will result in progeny in which fertility is completely restored and can lead

to the development of hybrid seed from which plants with fully restored fertility can be grown. The use of the RNase-inhibitor DNA for this purpose and the required procedures for transforming plants to make them fertility-restorer plants have been extensively described in EP 412 911 which is incorporated herein by reference.

The RNase DNAs of this invention, coding for RNases capable of forming only one intramolecular disulfide bridge (e.g., the sarnases), and the RNase-inhibitor DNAs of this invention, coding for specific inhibitors of such RNases (e.g., the sarstars), will be most useful in plants. However, these DNAs can be used to transform other eucaryotic organisms, in which it is desired either to disrupt the normal metabolism, functioning or development selectively of the cells of one or more specific tissues and/or organs of the organisms or to prevent such disruption.

The first and second chimaeric genes can also each comprise, or be fused to, a third chimaeric gene which contains, in the same transcriptional unit: a marker DNA encoding a marker RNA, protein or polypeptide which, when present at least in a specific tissue or specific cells of a transformed eucaryotic organism, particularly a plant, of this invention renders the organism easily separable or distinguishable from others which do not contain the marker RNA, protein or polypeptide at least in the specific tissue or specific cells; a third promoter fused to the 5' end of the marker DNA and capable of directing expression of the marker DNA at least in the specific tissue or specific cells; and suitable transcription termination signals, including a

polyadenylation signal, fused to the 3' end of the marker DNA.

The use of a particular marker DNA in each third chimaeric gene also is not believed critical, and if desired, the marker DNAs associated with each of the first and second chimaeric genes can be the same or different. Examples of suitable marker DNAs for plants are disclosed in EP 344 029, EP 412 006 and EP 412 911. In this regard, the marker DNAs can encode proteins or polypeptides inhibiting or neutralizing the activity of herbicides such as: the sfr gene and the sfrv gene encoding enzymes conferring resistance to glutamine synthetase inhibitors such as Bialophos and phosphinotricine as described in European patent application ("EPA") 87400544.0; and genes encoding modified target enzymes for certain herbicides that have a lower affinity for the herbicides than naturally produced endogenous enzymes, such as a modified glutamine synthetase as target for phosphinotricine as described in EP 240 792 and a modified 5-enolpyruvylshikimate-3 phosphate synthase as a target for glyphosate as described in EP 218 571.

In the first and second chimaeric genes of this invention, the use of particular first and/or second promoters is not believed critical, and if desired the first and second promoters can be the same. Examples of male organ-specific first and/or second plant promoters are the PTA29 promoter, the PTA26 promoter and the PTA13 promoter described in EP 344 029, which have been isolated from tobacco and are tapetum-specific promoters, and promoters of the plant genes encoding tapetum-specific mRNAs hybridizable to the genes TA29, TA26 or TA13 of EP 344 029, from which the PTA29, PTA26 and PTA13

promoters have been isolated, as well as the tapetum-specific promoters described in PCT publications WO 90/08825, WO 92/13956 and WO 92/13957. Examples of female organ-specific first and second plant promoters are described in EP 412 006.

In many cases, the second promoter (which controls the RNase-inhibitor DNA) and/or the third promoter (which controls the marker DNA) are preferably each a constitutive promoter whereby the RNase inhibitor DNA and/or the marker DNA will be expressed in the entire eucaryotic organism, e.g., plant. The selection of particular second or third promoters would then not be considered critical. Examples of suitable second and third constitutive plant promoters are disclosed in EP 344 029, EP 410 006 and EP 412 911, such as the strong constitutive 35S promoter (Odell et al (1985) Nature 313:810-812), 35S'3 promoter (Hull and Howell (1987) Virology 86:482-493), promoter of the nopaline synthetase gene ("PNOS") of the Ti-plasmid (Herrera-Estrella (1983) Nature 303:209-213) or promoter of the octopine synthase gene ("POCS" [De Greve et al (1982) J. Mol. Appl. Genet. 1 (6):499-511]).

In the chimaeric genes of this invention, 3' transcription termination signals can be selected from among those which are capable of providing correct transcription termination and polyadenylation of mRNA in plant cells. The transcription termination signals can be the natural ones of the RNase DNA or RNase-inhibitor DNA or heterologous. Examples of heterologous transcription termination signals are those of the octopine synthase gene (Gielen et al (1984) EMBO J. 3:835-845) and the T-DNA gene 7

(Velten and Schell (1985) Nucleic Acids Research ("NAR") 13:6981-6998).

Eucaryotic organisms can be transformed with the chimaeric genes of this invention in a conventional manner. In this regard, the cell of a plant, particularly a plant capable of being infected by Agrobacterium, can be suitably transformed using a vector that is a disarmed Ti-plasmid containing the first and third chimaeric genes of this invention or the second and third chimaeric genes of this invention and carried by Agrobacterium. This transformation can be carried out using the procedures described, for example, in EP 116 718 and EP 270 822. Preferred Ti-plasmid vectors contain one or more of the chimaeric genes of this invention between the border sequences, or at least located to the left of the right border sequence, of the T-DNA of the Ti-plasmid. Of course, other types of vectors can be used to transform the plant cell, using procedures such as direct gene transfer (as described, for example, in EP 233 247), pollen mediated transformation (as described, for example, in EP 270 356, PCT publication WO 85/01856, and US patent 4,684,611), plant RNA virus-mediated transformation (as described, for example, in EP 067 553 and US patent 4,407,956) and liposome-mediated transformation (as described, for example, in US patent 4,536,475). Cells of monocotyledonous plants, such as the major cereals including corn, rice, wheat, barley and rye, can be transformed as described in PCT patent publication WO 92/09696. If the plant to be transformed is corn, other recently developed methods also can be used such as, for example, the method described for certain lines of corn by: Fromm et al (1990) Bio/Technology 8:833;

Gordon-Kamm et al (1990) Bio/Technology 2:603; and Gould et al (1991) Plant Physiol. 95:426. If the plant to be transformed is rice, other recently developed methods can be used such as, for example, the method described for certain lines of rice by: Shimamoto et al (1989) Nature 338:274; Datta et al (1990) Bio/Technology 8:736; and Hayashimoto et al (1990) Plant Physiol. 93:857.

A transformed plant cell of this invention can be regenerated into a mature plant, and the resulting transformed plant can be used in a conventional breeding scheme to produce more transformed plants with the same characteristics or to introduce the first and/or second chimaeric genes of this invention in other varieties of the same or related plant species. Seeds obtained from the transformed plants contain each of the chimaeric genes of this invention as a stable genomic insert.

In the Examples which follow, all experimental procedures for manipulating recombinant DNA were carried out, unless otherwise indicated, by the standardized procedures described in Sambrook et al (1989) "Molecular Cloning: a Laboratory Manual, 2nd Edition", Cold Spring Harbor Laboratory Press, N.Y. Oligonucleotides were designed according to the general rules outlined by Kramer and Fritz (1968) Methods in Enzymology 154:350 and synthesized by the phosphoramidite method described by Beaucage and Caruthers (1981) Tetrahedron Letters 22:1859 on an applied Biosystems 380A DNA synthesizer (Applied Biosystems B.V., Maarssen, Netherlands).

The following bacterial strains and plasmids, used in the examples, are available from the Deutsche Sammlung für Mikroorganismen und Zellkulturen ("DSM"), Mascheroder Weg 1B, Braunschweig, Germany:

Bacterial strain	plasmid	DSM No.	Date of Deposit
<u>E.coli</u> WK6	pMa5-8	DSM 4567	May 3, 1988
<u>E.coli</u> WK6	pMc5-8	DSM 4566	May 3, 1988
<u>E.coli</u> MC1061	pMB3	DSM 4470	March 22, 1988
<u>E.coli</u> MC1061	pTTM6	DSM 4468	March 21, 1988
<u>E.coli</u> K514	pGSJ260	DSM 3606	December 12, 1985
<u>E.coli</u> MC1061(λ)	pEcoR251	DSM 4711	July 13, 1988
<u>Streptomyces aureofaciens</u> R08/26	-	DSM 6691	August 27, 1991

Examples

Example 1: Isolation and cloning of the R08/26 sarnase DNA from Streptomyces aureofaciens strain R08/26 (DSM 6691)

Total DNA of Streptomyces aureofaciens R08/26 (DSM 6691) was digested with PstI, and DNA fragments of 2.0 to 2.4 kb in length were isolated on LGT (low gelling temperature) agarose. Individual fragments were inserted in the PstI site of pEcoR252, and the resulting plasmids were transformed in E.coli MC1061 which were grown on LB medium supplemented with 100 mg/l ampicillin. Plasmid pEcoR252 was derived from pEcoR251 (DSM 4711) by exchanging a 253 bp BglIII-PvuI fragment of the β -lactamase gene of pEcoR251 with the corresponding fragment of pUC19 (Vanisch-Perron et al (1985) Gene 33:103).

300 clones were screened by means of colony hybridization, using Hybond N+ nylon membranes (Amersham Intl., PLC, Buckinghamshire, England) and a washing temperature of 30°C, with the following oligonucleotide probe:

TAT GGI TAT TAT CAT GAA TAT AC.

The oligonucleotide was constructed on the basis of the amino acids 49 to 56 (Tyr-Gly-Tyr-Tyr-His-Glu-Tyr-Thr) of the known amino acid sequence of the sarnase, RNase Sa, from *S. aureofaciens* Type BMK (Shlyapnikov et al, supra).

Three positive clones were identified which were all shown to carry an identical 2.2 kb insert in the same orientation. This clone was named pEcoR252/P1. The restriction map of the insert was determined (see Fig. 1), and the insert was sequenced according to Maxam and Gilbert (1980) Methods in Enzymology 65:499. The sequence of a 977 bp fragment containing the sequence coding for the R08/26 sarnase is given in SEQ ID no. 1.

The expression vector pMa5-19 was derived from pMa5-8 (DSM 4567) as follows. The EcoRI-HindIII fragment of plasmid pMT416, containing the barnase gene, as described by Hartley (1988) J. Mol. Biol. 202:913, was cloned between the EcoRI and HindIII sites of pMa5-8. The sequence at the transition of the PhoA signal sequence and the barnase coding sequence was changed from GCC GCA CAG to GCG GTA CCG by site-directed mutagenesis, thus introducing a KpnI site. Subsequently the GTG initiation codon of the PhoA signal sequence was changed to ATG by site-directed mutagenesis. Finally, the sequence between the KpnI site and the HindIII site was replaced with

the KpnI-HindIII fragment of pUC19 containing the polylinker of pUC19.

Using the analogous procedure, plasmid pMc5-19 is derived from pMc5-8 (DSM 4566) and from pMa5-19 (Stanssens et al (1989) NAR 17:4441). The sequence of the plasmid, pMac5-19, is given in SEQ ID. no. 2.

pMa5-19 and pMc5-19 contain the tac-promoter and the PhoA signal sequence from pMT416, flanked at the 3' end with most of the polylinker of pUC19. pMa5-19 and pMc5-19, like pMa5-8 and pMc5-8, can be introduced in *E. coli* WK6 (Zell and Fritz (1987) EMBO J. 6:1809), and the bacteria can then be grown in minimal medium supplemented with 100 mg/l ampicillin for pMa5-19 or with 25 mg/l chloramphenicol for pMc5-19. In *E. coli* strains that overproduce the lac repressor, such as strain WK6, the expression of a gene under the control of the tac promoter can be regulated. While normally repressed, gene expression can be induced by addition of a commonly used inducer of the lac operon, IPTG (isopropyl- β -D-thiogalactopyranoside). Plasmids pMa5-8 and pMc5-8 and derivatives thereof, such as pMa5-19 and pMc5-19, can be used for site-directed mutagenesis by a gapped duplex DNA method using alternating selectable markers (Stanssens et al (1989) NAR 17:4441; EPA 87402348.4).

Because the cloning of the complete gene encoding R08/26 sarnase in the expression vectors pMa5-19 or pMc5-19 was expected to have toxic effects on the host cell, it was decided to prepare subclones of two overlapping parts of the R08/26 sarnase gene. Where required during the cloning procedures, the orientation of cloned inserts was checked by means of restriction mapping or sequencing. To clone the proximal part of the R08/26 sarnase gene, plasmid

pEcoR252/P1 was cleaved with StyI, filled in with the large fragment of DNA Polymerase I of E.coli (Klenow), and cleaved again with ScaI, and the 335 bp fragment was cloned in the SmaI site of pMc5-19, yielding plasmid pMc5-19/Sty-Sca. For further manipulation, a FspI site was created immediately upstream the presumed coding sequence (starting with Ala-Asp) of the mature R08/26 sarnase. The gapped duplex DNA was constructed from the single stranded pMa5-19/Sty-Sca and the large KpnI-Tth111I fragment of pMc5-19/Sty-Sca. For mutagenesis, use was made of the following oligonucleotide:

GCCGGGTCTGCGCACGTCCAGGCG

yielding plasmid pMc5-19/Mut-Fsp. Finally, a deletion was made by ligating the 2274 bp FspI fragment of pMc5-19/Mut-Fsp and the 1970 bp KpnI (filled-in with Klenow)-FspI fragment of pMa5-19/Tth-Ava (see below), yielding pMa5-19/deltaKF.

To clone the distal part of the R08/26 sarnase gene, plasmid pEcoR252/P1 was cleaved with Tth111I, filled in with Klenow, and cleaved again with AvaI, and the 347 bp fragment was cloned in the SmaI site of pMc5-19. A 583 bp EcoRI-HindIII fragment was isolated from DNA prepared from the mixture of transformants and cloned between the EcoRI and HindIII sites of pMa5-8, yielding plasmid pMa5-19/Tth-Ava. The 3' end of the distal part of the R08/26 sarnase gene was then deleted by cleaving pMa5-19/Tth-Ava with SphI, filling in with Klenow, cleaving with Eco47III and religating, yielding pMa5-19/deltaES.

Both parts of the R08/26 sarnase gene were then joined as follows. The large EcoRI-BstEII fragment of pMa5-19/deltaES was ligated to the 370 bp EcoRI-

BstEII fragment of pMa5-19/deltaKF, yielding pMa5-19/Sarnasel. The large EcoRI-BstEII fragment of pMa5-19/deltaES was also ligated to the 470 bp EcoRI-BstEII fragment of pMa5-19/Mut-Fsp, yielding pMa5-19/Sarnpgs1. pMa5-19/Sarnasel, containing the mature R08/26 sarnase coding sequence immediately behind the tac-PhoA region, can be used for expression of R08/26 sarnase in E. coli. pMa5-19/Sarnpgs1 contains the mature R08/26 sarnase sequence as a 306 bp FspI-XbaI or as a 298 bp FspI-HindIII fragment. These fragments can therefore be used for the construction of gene cassettes for plant transformation (see Example 7).

Surprisingly, the amino acid sequence of the R08/26 sarnase isolated from S. aerofaciens R08/26 is quite different from that of the sarnase, RNase Sa, isolated from S. aureofaciens (Shlyapnikov et al (1986) FEBS Letters 209:335). The differences between the two sarnases could be due to their bacterial sources. In this regard, the R08/26 sarnase codes for a RNase with a quite different amino acid sequence having only about 50% homology to the amino acid sequence of RNase Sa. R08/26 sarnase has only two cysteine residues which are homologous to the cysteine residues in RNase Sa that are involved in disulfide bridge formation (Sevcik et al (1991) Acta Cryst. B47:240). It is highly likely that the two cysteines of R08/26 sarnase also form its disulfide bridge.

Example 2: Comparison of ribonuclease expression on viability of E.coli.

The expression and secretion of ribonucleases in transformed E. coli WK6 and the effects of the ribonucleases on the viability of the host cells were compared in host cells transformed with

pMa5-19/Sarnase of Example 1 and the similar constructs pMa5-RT1 and pMa5-Barnase containing respectively the Rnase T1 gene from Aspergillus oryzae and barnase gene from B. amyloliquefaciens.

pMa5-RT1 was derived from pMa5-8 and contains the tac-PhoA-RnaseT1 gene cassette. Its construction has been described in Steyaert et al (1990) Biochemistry 29:9064.

pMa5-Barnase was constructed by cloning the EcoRI-HindIII fragment of pMT416 (Hartley (1988) J.Mol.Biol. 202:913) between the EcoRI and HindIII sites of pMa5-8. This construct also contains an expressible barstar gene from B. amyloliquefaciens.

The effects of pMa5-19/Sarnase1, pMa5-RT1 and pMa5-Barnase in E.coli WK6 on the growth curves of uninduced and induced bacteria were ascertained according to Steyaert et al (1990), supra, and the results are qualitatively summarized in the following table.

Plasmid	Expressed genes	cell growth repressed conditions	cell growth after IPTG induction
pMa5-19	None	+++	+++
pMa5-RT1	RNase T1	+++	++
pMa5-19/Sarnase1	R08/26 Sarnase	+	-
pMa5-Barnase	Barnase/Barstar *	+	-

* Expression of barnase alone (without barstar) is lethal even under repressed conditions (Hartley (1989) TIBS 14:450).

These results indicate that the effect of expression of the R08/26 sarnase gene in E. coli is intermediate with respect to that observed with RNase T1 and barnase. It is believed that this is due to the presence of a single disulfide bridge in the R08/26 sarnase. Disulfide bridges are formed only with difficulty in the reducing intracellular environment while, to be active, enzymes require such bridges to be properly formed. If no disulfide bridges are present (as in barnase), the enzyme is always active, and its presence in the cell is lethal. If two disulfide bridges are present (as in RNase T1), almost no active enzyme is produced intracellularly, even after induction. With only one disulfide bridge, as in a sarnase, a larger proportion of active enzyme is produced which is reflected in the reduced viability of the repressed host cells and the complete loss of viability after induction.

Example 3: Cloning of the R08/26 sarstar gene from S. aureofaciens R08/26 by positive selection from E. coli

The BamHI (filled-in with Klenow)-EcoRI fragment of plasmid pEcoR252 (from Example 1), containing the gene coding for the EcoRI restriction endonuclease under control of the P_r promoter, is ligated to the large BssHI (filled-in with Klenow)-EcoRI fragment of plasmid pMa5-19/sarnpgs1 (from Example 1) yielding plasmid pMa5-19/sarnpgs2.

The total DNA obtained from S. aureofaciens R08/26 is partially digested with Sau3AI. Fragments with sizes ranging from 4 kb to 10 kb are isolated using LGT agarose electrophoresis and are ligated to pMa5-19/sarnpgs2 linearized with BglII. The ligation mixture is used to transform competent cells of

E.coli WK6. Transformants are grown on LB agar plates supplemented with IPTG (final concentration 0.1 mM). Positive clones, which are thought to express the gene coding for the R08/26 sarnase inhibitor (R08/26 sarstar) using the P_R promoter and its own translational signals, are further analyzed using restriction analysis, sequencing and inhibitor activity estimation (Mucha et al (1983a) *Biologia* 38:1177) to isolate the R08/26 sarstar DNA.

Example 4: Cloning of the R08/26 sarstar gene from *S. aureofaciens* R08/26 by positive selection in *Streptomyces lividans*

Total DNA from *S. aureofaciens* R08/26 is partially digested with Sau3AI. Fragments with sizes ranging from 4 kb to 10 kb are isolated using LGT agarose electrophoresis and are ligated to pKJ4/P1 linearized with BglII or BamHI. pKJ4/P1 is a shuttle vector for *E. coli* and *Streptomyces* (Nazarov and Godany (1991) In "Metabolism and enzymology of nucleic acids including gene and protein engineering" -Balan J., ed. - Czechoslovakian Academy of Sciences, Proceedings of a symposium held in Bratislava on November 26-30, 1990, pp. 117-123). The ligation mixture is used to transform competent cells of *E. coli* MC1061. Recombinant plasmids are isolated from transformants and used to transform *Streptomyces lividans* 66 protoplasts (see Thompson et al (1987) *EMBO J* 6:2519). Plasmids from positive clones are analyzed using direct inhibitor activity estimation. After transfer into *E. coli*, the plasmids are further characterized by means of restriction analysis and sequencing to isolate the R08/26 sarstar DNA.

Example 5: Cloning of the R08/26 sarstar gene from *S. aureofaciens* R08/26 by oligonucleotide screening of a genomic library

R08/26 sarstar is purified from *S. aureofaciens* R08/26 according to the procedures described by Mucha et al (1983a) supra. The N-terminal sequence of the R08/26 sarstar is then determined using procedures as described by Bauw et al (1987) Proc. Natl. Acad. Sci. USA ("PNAS") 84:4806. On the basis of the N-terminal amino acid sequence, a number of oligonucleotides encoding the sequence are then designed and synthesized to screen, by means of nucleic acid hybridization, a genomic DNA library of *S. aureofaciens* R08/26. The genomic library is obtained by digestion of total DNA of the strain with Sau3AI and cloning of the DNA fragments in pUC19 in *E.coli* MC1061. Positive clones are then further analyzed by restriction enzyme mapping and DNA sequencing to isolate the R08/26 sarstar DNA.

Example 6: Comparison of RNase T1, barnase and R08/26 sarnase as cytotoxic gene products in plant cells.

Expression of the barnase gene from *B. amyloliquefaciens* and the RNase T1 gene from *A. oryzae* under the control of a plant promoter specifically active in the tapetal cell layer has shown that the expression of the corresponding ribonuclease causes male sterility in plants (Mariani et al, supra).

To evaluate the efficacy of RNase T1, barnase and R08/26 sarnase in plant cells, analyses are performed based on transient expression assays (Denecke et al (1989) Methods Mol. Cell Biol. 1:19). A DNA encoding each ribonuclease is placed under the control of the constitutive CaMV 35S promoter. To measure the lethal effect of the expression of each

ribonuclease, a marker gene construct, together with the ribonuclease-encoding DNA, is introduced in plant protoplasts. The marker gene is gus (Jefferson et al (1987) EMBO J. 6:3901). The expression of each ribonuclease and its impact on cell metabolism is indirectly measured by the gus expression profile. The presence or absence of the ribonuclease in the plant cell is modulated by using plasmid DNA linearized respectively outside or inside the coding region of the ribonuclease-encoding DNA. Upon electroporation of the linearized DNA, the gus expression profile is followed as a function of time and gene dosage in order to compare the effects of the different ribonucleases.

Small plasmids, pTE4, are used in order to reduce the impact of plasmid size on transient expression assays, and each plasmid contains a chimeric gus gene construct and a chimeric ribonuclease gene construct. pTE4 is shown in Fig. 2, and its complete sequence is shown in SEQ ID no. 3. pTE4 is a pUC18 derived plasmid containing two chimaeric genes cloned in the polylinker. One of these genes is the pnos-gus-3'nos gene which consists of a pnos promoter fragment (De Picker et al (1982) J.Mol.Appl.Genet. 1:561), the GUS coding sequence (Jefferson et al, supra) and the 3' untranslated end of nopaline synthase (Gielen et al (1984) EMBO J 3:835). The other chimeric gene is a CaMV 35S-barnase-3'ocs gene construct which consists of a CaMV 35S promoter fragment (EP 359 617), the barnase coding region and the 3' untranslated end of octopine synthase (Ingelbrecht et al (1989) The Plant Cell 1:671).

pTE4 can only be propagated in a host strain carrying an active barstar gene. To this end, the

strain WK6(pMc5BS) is used. Plasmid pMc5BS contains the barstar gene under the control of the tac promoter and is constructed by cloning the EcoRI-HindIII fragment of pMT416 (Hartley, supra) in pMc5-8 (DSM 4566).

Then, the sequence, starting with the initiation codon of the phoA signal sequence and ending with the last nucleotide before the translation initiation codon of the barstar coding region, is deleted by looping-out mutagenesis according to the general procedures described by Sollazzo et al (1985) Gene 37:199. The availability of an ampicillin resistance gene on pTE4 and a chloramphenicol resistance gene on pMc5BS permits the strains to be kept stable on plates provided with the two antibiotics.

To obtain comparable plasmids with the RNase T1 and R08/26 sarnase coding region, the following constructs are made :

- pCV10 : the HindIII (filled-in with Klenow.) - NcoI restriction fragment of pTE4 containing barnase-3'nos is replaced by the EcoRI (filled-in with Klenow.) -NcoI fragment containing RNase T1-3'nos from pTTM6 (DSM 4468).
- pCV9 : the HindIII-NcoI restriction fragment of pTE4 containing barnase-3'nos is replaced by the HindIII-NcoI fragment containing R08/26 sarnase-3'nos from pCO50 (see Example 7).

The plasmids pTE4, pCV9 and pCV10 are linearized in two different ways: 1) by cleavage of a unique site within the coding region of the ribonuclease-encoding DNA (SmaI in pTE4, BamHI in pCV9 and BstEII in pCV10), and 2) by cleavage of a unique site outside of the chimeric gene constructs (PvuI in all cases). Linearized plasmid DNA is electroporated in mesophyll protoplasts prepared from leaves of SR1,

and GUS activities are measured as described by Denecke et al, supra. In all cases in which an intact ribonuclease DNA is introduced in plant protoplasts together with an intact gus gene, the GUS activity profile, as a function of time, is significantly quenched. However, as compared to the control situations in which protoplasts are electroporated with plasmid DNA linearized within the ribonuclease coding region (so that only an intact gus gene is present), GUS activity is most quenched by expression of barnase (pTE4) and less quenched by expression of RNase T1 (pCV10). Expression of R08/26 sarnase (pCV9) results in a level of quenching of GUS activity that is intermediate with respect to the expression of barnase and the expression of RNase T1. This indicates that the toxic effect of sarnase expression in plant cells is intermediate to those of barnase expression and RNase T1 expression. The differences in toxic effects among the three ribonuclease-encoding genes may be due to differences in efficiency of transcription/translation of the respective genes and/or of post-translational processes that have an effect on enzyme activity (e.g. proper folding and disulfide bridge formation). However, as the three ribonuclease-encoding DNAs are under the control of identical regulatory signals, it is believed that the differences in enzyme activity (as measured by the degree of GUS activity quenching) are most likely due to differences in the efficiency of protein folding and disulfide bridge formation.

In order to better define the differences in toxic effects of the three ribonuclease-encoding genes of this experiment, it is repeated with plasmids pTE4, pCV9 and pCV10 each containing an intron in its respective ribonuclease coding

sequence. In this regard, the barnase coding sequence in plasmid pTE4 is replaced by the barnase coding sequence, containing the TA36 intron, described in PCT patent publication WO 92/13957. Similarly, the sarnase DNA in pCV9 is replaced with DNA coding for sarnase but containing, at an appropriate place, the TA36 intron, and the DNA coding for RNase T1 in pCV10 is replaced with DNA coding for RNase T1 but containing, at an appropriate site, the TA36 intron. Appropriate sites for insertion of the TA36 intron are determined according to well known general rules outlined, for example, in Goodall and Filipowicz (1989) Cell 58:473 and Hanley and Schuler (1988) Nucleic Acids Research 16:7159.

Example 7: Construction of T-DNA vectors, each containing the R08/26 sarnase coding region or the R08/26 sarstar coding region under the control of the tapetum specific promoter, PTA29.

A T-DNA vector carrying the R08/26 sarnase DNA of Example 1 under the control of the tapetum specific TA29 promoter, similar to the RNase T1-encoding pTTM6A and the barnase-encoding pTTM8 of EP 344 029, is constructed. In a first step, the R08/26 sarnase DNA is provided with a fragment for transcription termination and polyadenylation (3'ocs) as follows: a HindIII-EcoRI fragment from pMa5-19/sarnpgs1 is cloned in pOCS1 digested with SmaI and EcoRI, yielding pCO49. Plasmid pOCS1 is constructed by ligating the 0.7 kbp PvuII fragment comprising the 3' untranslated end of the octopine synthase gene of the T-DNA from Agrobacterium tumefaciens, as described by Ingelbrecht et al (1989) The Plant Cell 1:671, in the HindII site of plasmid pUC19 (Yanisch-Perron et al (1985) Gene 33:103). In a second step, a chimeric PTA29-R08/26 sarnase-3'ocs

gene construct is made by combining i) a NcoI (filled-in with Klenow)-EcoRI fragment of pMB3 (DSM 4470) containing the PTA29 promoter (EP 344 029), ii) a FspI-HindIII fragment of pC049 containing the sarnase-3'ocs fragment, and iii) the large EcoRI-HindIII fragment of pMC5-8, yielding the plasmid pC050. Subsequently, the EcoRI-HindIII fragment (filled-in with Klenow) of pC050, containing the chimeric PTA29-sarnase-3'ocs gene, is cloned between the T-DNA borders of pGSJ260 (DSM 3606) by ligation with the large BamHI (filled-in with Klenow)-StuI fragment of pGSJ260. This yields the plasmid pTC053, carrying a chimeric PTA29-R08/26 sarnase-3'ocs gene and a pnos-neo-3'ocs gene construct between the T-DNA border repeats.

Using an analagous procedure, a T-DNA vector is constructed carrying the R08/26 sarstar DNA of Examples 3, 4 and 5 under the control of the tapetum-specific PTA29 promoter, similar to the barstar-encoding vector, pTVE74, of EP 412 911.

The two resulting plasmid vectors are mobilized in *Agrobacterium tumefaciens* strain C58C1Rif(pGV2260) as described by Deblaere et al (1987) Meth. Enzymol. 153:277, yielding the sarnase DNA-containing strain C58C1Rif(pTC01053) and the sarstar DNA-containing strain C58C1Rif(pTC01054), which has subsequently been renamed as "C58C1Rif(pTC01053*)." .

Example 8: Plant transformations with chimeric genes of Example 7 containing the R08/26 sarnase or sarstar coding region under the control of the TA29 promoter

The *Agrobacterium tumefaciens* strains C58C1Rif (pTC01053 and pTC01054) of Example 7 are used to transform lettuce (*Lactuca sativa*) according to the procedures described by Micheltore et al (1987) Plant Cell Reports 6:439 and tobacco (*Nicotiana tabacum*) as

described for the barnase and RNase T1 chimeric constructs in EP 344 029 and EP 412 911. The resulting transformed plants are normal except for their flowers. In this regard, each plant containing the R08/26 barnase DNA under the control of the TA29 tapetum-specific promoter expresses such DNA at least predominantly in its anthers and produces no normal pollen (i.e., the plant is considered to be male-sterile), and each plant containing the R08/26 sarstar DNA under the control of the TA29 promoter expresses such DNA at least predominantly in its anthers but produces normal pollen (i.e. the plant is a male-fertility restorer plant for the corresponding male-sterile plant of this Example). By crossing the male-sterile plants transformed with the R08/26 barnase DNA with the corresponding male-fertility restorer plants transformed with the R08/26 sarstar DNA, fertile seed-bearing plants are obtained.

Needless to say, this invention is not limited to the transformation of any specific eucaryotic organism(s) or plant(s). The invention relates to any eucaryotic organism, particularly a plant, the nuclear genome of which can be transformed with the RNase DNA, preferably the barnase DNA, under the control of the first promoter or with the RNase-inhibitor DNA, preferably the sarstar DNA, under the control of the second promoter. For example, this invention relates to plants such as corn, oilseed rape, wheat, rice, sunflower, sugarbeet, tomato, lettuce, peppers, sorghum, soybean, pea, alfalfa, grasses, clover, carrot, cabbages, leek, onion, tobacco, petunia, cacao and citrus trees.

Also this invention is not limited to the specific plasmids and vectors described in the foregoing Examples, but rather encompasses any

plasmids and vectors containing the RNase DNA or RNase-inhibitor DNA.

Furthermore, this invention is not limited to the specific first and second promoters described in the foregoing Examples, i.e., the PTA29 promoter, but rather encompasses any DNA sequence encoding a first promoter capable of directing expression of a RNase DNA substantially selectively in cells of a specific organ and/or tissue of a eucaryotic organism, preferably a plant, particularly in the plant's flowers, seeds or embryos, or encoding a second promoter capable of directing expression of a RNase-inhibitor DNA at least in the cells of the organism where the RNase DNA is to be expressed.

In addition, this invention is not limited to the specific RNase and RNase-inhibitor DNAs described in the foregoing Examples but rather encompasses any equivalent DNA sequences encoding respectively: a RNase that would significantly disturb adversely the metabolism, functioning and/or development of eucaryotic cells, preferably plant cells, in which the equivalent RNase DNA is expressed under the control of the first promoter; and a RNase-inhibitor that, in a cell in which the equivalent RNase-inhibitor DNA is expressed under the control of the second promoter, would neutralize, block, offset, overcome or otherwise prevent the activity of the RNase encoded by the equivalent RNase DNA. In this regard, sarnase DNA and sarstar DNA sequences, other than those present naturally in S. aureofaciens strains and encoding natural sarnases and sarstars, can be used in accordance with this invention. Indeed, the natural sequences of the R08/26 sarnase and sarstar DNAs of this invention can be modified by: 1) replacing some codons with others that code

either for the same amino acids or for other amino acids; and/or 2) deleting or adding some codons -- provided that such modifications do not substantially alter the properties, particularly the respective ribonuclease and ribonuclease-inhibiting properties, of the encoded R08/26 sarnases and sarstars. For example, the mature R08/26 sarnase of SEQ ID no. 1 can have its N-terminal end modified (e.g., by a methionine) to have proper expression of the sarnase within a eucaryotic organism.

Also this invention is not limited to the specific marker DNAs described in the foregoing Examples but rather encompasses any marker DNA encoding an RNA, protein or polypeptide that confers on at least a specific tissue or specific cells of the eucaryotic organism, particularly a plant, in which the marker DNA is expressed, a distinctive trait compared to such a specific tissue or specific cells in which the marker DNA is not expressed.

SEQUENCE LISTING

1. General Information
 - i) APPLICANT : PLANT GENETIC SYSTEMS N.V.
 - ii) TITLE OF INVENTION : A Novel Ribonuclease And Its Inhibitor
 - iii) NUMBER OF SEQUENCES : 3
 - iv) CORRESPONDENCE ADDRESS :
 - A. ADDRESSEE : Plant Genetic Systems N.V.
 - B. STREET : Plateaustraat 22
 - C. POSTAL CODE AND CITY : 9000 Ghent
 - D. COUNTRY : Belgium
 - v) COMPUTER READABLE FORM :
 - A. MEDIUM TYPE : 5.25 inch, double sided, high density 1.2 Mb floppy disk
 - B. COMPUTER IBM PC/AT
 - C. OPERATING SYSTEM : DOS version 3.3
 - D. SOFTWARE : Wordperfect 5.1
 - vi) CURRENT APPLICATION DATA : Not Available
 - vii) PRIOR APPLICATION DATA : EP 91402767,7
filed October 16, 1991

2. Sequence Description : SEQ ID NO. 1

SEQUENCE TYPE: DNA sequence with corresponding amino acid sequence for a protein, R08/26 sarnase
 SEQUENCE LENGTH: 977 bp and 163 translated amino acids

STRANDEDNESS: double stranded
 TOPOLOGY: linear
 MOLECULAR TYPE: genomic DNA

ORIGINAL SOURCE:

ORGANISM: Streptomyces aureofaciens R08/26

FEATURES:

- nucleotide 149 to nucleotide 640 : coding sequence of sarnase precursor, including a signal sequence
- nucleotide 347 to nucleotide 640 : presumed coding sequence of mature sarnase
- nucleotide 129 : cleavage site NarI
- nucleotide 221 : cleavage site KpnI
- nucleotide 253 : cleavage site StyI
- nucleotide 347 : cleavage site FspI (not present in sequence, but introduced by site directed mutagenesis of sequence 344-349 from CCCGCC to TGCGCA).
- nucleotide 453 : cleavage site Tth111I
- nucleotide 524 : cleavage site BstEII
- nucleotide 588 : cleavage site ScaI
- nucleotide 643 : cleavage site Eco47III
- nucleotide 800 : cleavage site AvaI

PROPERTIES: The mature protein is a guanyl specific ribonuclease

CGGCGGAACG	GACAACGGCG	TCCGTCCCGC	CCGGCCGTAC	GTCCTTGTGG	50
TGTCGGCGGG	CGGTGCCCCG	CGCGTGCTGC	TCGTCGTGTG	GTGTCCGTCA	100
TGTGTGGGAC	ACGGCCGGCC	GGCGCGGGCG	CCTGCCAAGC	TGGACCGC	148

ATG	ACC	AGA	AGC	AAG	AGC	CCG	CTC	GTC	GTC	GGG	GCC	GTC	187
MET	Thr	Arg	Ser	Lys	Ser	Pro	Leu	Val	Val	Gly	Ala	Val	
	-65					-60					-55		

CTG	ATC	CTG	GCC	GTG	CTC	GCC	GGG	GTT	GGG	TAC	CTG	CTC	226
Leu	Ile	Leu	Ala	Val	Leu	Ala	Gly	Val	Gly	Tyr	Leu	Leu	
	-50						-45						

GCC	GGC	AGG	GGC	GGC	AGC	ACC	CAC	CCC	AAG	GCC	GCC	GCG	265
Ala	Gly	Arg	Gly	Gly	Ser	Thr	His	Pro	Lys	Ala	Ala	Ala	
-40					-35					-30			

AGC TCC GCC GCC GCG GGC ACC TCG GCC CCC AAA TCC TCG Ser Ser Ala Ala Ala Gly Thr Ser Ala Pro Lys Ser Ser -25 -20 -15	304
GCT CCC AAG CCG TCC CCG CCC GCC GGC GGC GCC TGG ACG Ala Pro Lys Pro Ser Pro Pro Ala Gly Gly Ala Trp Thr -10 -5	343
CCC GCC GAC CCG GCG CTG GCC GAC GTC TGC CGC ACC AAG Pro Ala Asp Pro Ala Leu Ala Asp Val Cys Arg Thr Lys 1 5 10	382
CTG CCC AGC CAG GCC CAG GAC ACC CTC GCC CTG ATC GCC Leu Pro Ser Gln Ala Gln Asp Thr Leu Ala Leu Ile Ala 15 20 25	421
AAG AAC GGC CCC TAC CCG TAC AAC CGG GAC GGC GTC GTC Lys Asn Gly Pro Tyr Pro Tyr Asn Arg Asp Gly Val Val 30 35	460
TTC GAG AAC CGC GAG AGC CGC CTG CCG AAG AAG GGC AAC Phe Glu Asn Arg Glu Ser Arg Leu Pro Lys Lys Gly Asn 40 45 50	499
GGC TAC TAC CAC GAG TTC ACC GTG GTC ACC CCC GGC TCC Gly Tyr Tyr His Glu Phe Thr Val Val Thr Pro Gly Ser 55 60	538
AAC GAC CGA GGC ACC CGA CGG GTC GTC ACC GGC GGC TAC Asn Asp Arg Gly Thr Arg Arg Val Val Thr Gly Gly Tyr 65 70 75	577
GGC GAG CAG TAC TGG TCC CCG GAC CAC TAC GCG ACC TTC Gly Glu Gln Tyr Trp Ser Pro Asp His Tyr Ala Thr Phe 80 85 90	616
CAG GAG ATC GAC CCG CGC TGC TGA GCGCTNGCCT CACAGAAAAT Gln Glu Ile Asp Pro Arg Cys 95	660
ACTTTCCAAC CTGGAAAGGT CGTGGCACAG TGGAGCCACC GTCAC TTTC	710
GAGGGGGAAA CATGAGTGAC TCCGCTCCCA CCCC GCCGTC CGCCGCCGAG	760
GCACNGCCTG CCGACCGGGC CGGCGCGGCT GCCCGGCCGC CGGGCGAGCT	810
GCCCCGCTGG TACGGGCGCG CTTTCGCCTT CGCCTTCGCG CTCTACGGCC	860
TGGGGATCGG CCACGTCATC GAGACCGGGC AGATCGCCGT GATCGGCGGG	910
CTCGCNCCTT GCCGCCCTGA CCGGTGGCCT CGCGGCCTTC GCCATGCGCA	960
GCGACGGCAT CGTCCGC	977

3. Sequence Description : SEQ ID NO. 2

SEQUENCE TYPE: DNA sequence for an expression vector, pMac5-19.
SEQUENCE LENGTH: 4005 bp

STRANDEDNESS: double stranded

TOPOLOGY: circular

MOLECULAR TYPE: plasmid DNA replicable in E.coli

FEATURES: - nucleotide 3754 to nucleotide 3884 : tac promoter
- nucleotide 3885 to nucleotide 3947 : PhoA signal sequence
- nucleotide 3947 to nucleotide 3993 : part of pUC19 polylinker (KpnI, SmaI, BamHI, XbaI, SalI, BspMI, PstI, SphI, HindIII)

PROPERTIES: pMac5-19 is the basic expression vector from which pMa5-19 and pMc5-19 can be derived. The latter plasmids can be used for site directed mutagenesis by a gapped duplex DNA method using alternating selectable markers as described by Stanssens et al (1989) NAR 17:4441. In pMc5-19 the G-residue at position 2238 of pMac5-19 is replaced by a C which results in the insertion of an amber codon in the bla-am gene. In pMa5-19 the G-residue at position 3409 of pMac5-19 is replaced by a A which results in the insertion of an amber codon in the cat gene.

AATTCACCTC	GAAAGCAAGC	TGATAAACCG	ATACAATTAA	AGGCTCCTTT	50
TGGAGCCTTT	TTTTTTGGAG	ATTTTCAACG	TGAAAAAATT	ATTATTCGCA	100
ATTCCAAGCT	AATTCACCTC	GAAAGCAAGC	TGATAAACCG	ATACAATTAA	150
AGGCTCCTTT	TGGAGCCTTT	TTTTTTGGAG	ATTTTCAACG	TGAAAAAATT	200
ATTATTCGCA	ATTCCAAGCT	CTGCCTCGCG	CGTTTCGGTG	ATGACGGTGA	250
AAACCTCTGA	CACATGCAGC	TCCCGGAGAC	GGTCACAGCT	TGTCTGTAAG	300
CGGATGCAGA	TCACGCGCCC	TGTAGCGGCG	CATTAAGCGC	GGCGGGTGTG	350
GTGGTTACGC	GCAGCGTGAC	CGCTACACTT	GCCAGCGCCC	TAGCGCCCGC	400
TCCTTTCGCT	TTCTTCCCTT	CCTTTCTCGC	CACGTTCCGC	GGCTTTCCCC	450
GTCAAGCTCT	AAATCGGGGG	CTCCCTTTAG	GGTTCGATT	TAGTGCTTTA	500
CGGCACCTCG	ACCCCAAAAA	ACTTGATTAG	GGTGATGGTT	CACGTAGTGG	550
GCCATCGCCC	TGATAGACGG	TTTTTCGCCC	TTTGACGTTG	GAGTCCACGT	600
TCTTTAATAG	TGGACTCTTG	TTCCAAACTG	GAACAACACT	CAACCCTATC	650
TCGGTCTATT	CTTTTGATT	ATAAGGGATT	TTGCCGATTT	CGGCCTATTG	700
GTTAAAAAAT	GAGCTGATT	AACAAAAATT	TAACGCGAAT	TTTAACAAAA	750
TATTAACGTT	TACAATTTGA	TCTGCGCTCG	GTCGTTCGGC	TGCGGCGAGC	800
GGTATCAGCT	CACTCAAAGG	CGGTAATACG	GTTATCCACA	GAATCAGGGG	850
ATAACGCAGG	AAAGAACAATG	TGAGCAAAAAG	GCCAGCAAAA	GGCCAGGAAC	900
CGTAAAAAAG	CCGCGTTGCT	GGCGTTTTTC	CATAGGCTCC	GCCCCCTGA	950

CGAGCATCAC	AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	1000
GACTATAAAG	ATACCAGGCG	TTTCCCCCTG	GAAGCTCCCT	CGTGCGCTCT	1050
CCTGTTCCGA	CCCTGCCGCT	TACCGGATAC	CTGTCCGCCT	TTCTCCCTTC	1100
GGGAAGCGTG	GCGCTTTCTC	AATGCTCAGC	CTGTAGGTAT	CTCAGTTCGG	1150
TGTAGGTCGT	TCGCTCCAAG	CTGGGCTGTG	TGCACGAACC	CCCCGTTTCA	1200
CCCGACCGCT	GCGCCTTATC	CGGTAACAT	CGTCTTGAGT	CCAACCCGGT	1250
AAGACACGAC	TTATCGCCAC	TGGCAGCAGC	CACTGGTAAC	AGGATTAGCA	1300
GAGCGAGGTA	TGTAGGCGGT	GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	1350
TACGGCTACA	CTAGAAGGAC	AGTATTTGGT	ATCTGCGCTC	TGCTGAAGCC	1400
AGTTACCTTC	GGAAAAAGAG	TTGGTAGCTC	TTGATCCGGC	AAACAAACCA	1450
CCGCTGGTAG	CGGTGGTTTT	TTTGTGTCGA	AGCAGCAGAT	TACGCGCAGA	1500
AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	GGTCTGACGC	1550
TCAGTGGAAC	GAAAACTCAC	GTTAAGGGAT	TTTGGTCATG	AGATTATCAA	1600
AAAGGATCTT	CACCTAGATC	CTTTTAAATT	AAAAATGAAG	TTTTAAATCA	1650
ATCTAAAGTA	TATATGAGTA	AACTTGGTCT	GACAGTTACC	AATGCTTAAT	1700
CAGTGAGGCA	CCTATCTCAG	CGATCTGTCT	ATTTCTGTTCA	TCCATAGTTG	1750
CCTGACTCCC	CGTCGTGTAG	ATAACTACGA	TACGGGAGGG	CTTACCATCT	1800
GGCCCCAGTG	CTGCAATGAT	ACCGCGAGAC	CCACGCTCAC	CGGCTCCAGA	1850
TTTATCAGCA	ATAAACCAGC	CAGCCGGAAG	GGCCGAGCGC	AGAAGTGGTC	1900
CTGCAACTTT	ATCCGCCTCC	ATCCAGTCTA	TTAATTGTTG	CCGGGAAGCT	1950
AGAGTAAGTA	GTTTCGCCAGT	TAATAGTTTG	CGCAACGTTG	TTGCCATTGC	2000
TGCAGGCAATC	GTGGTGTAC	GCTCGTCGTT	TGGTATGGCT	TCATTTCAGCT	2050
CCGGTTCCCA	ACGATCAAGG	CGAGTTACAT	GATCCCCCAT	GTTGTGCAAA	2100
AAAGCGGTTA	GCTCCTTCGG	TCCTCCGATC	GTTGTCAGAA	GTAAGTTGGC	2150
CGCAGTGTTA	TCATCTCATGG	TTATGGCAGC	ACTGCATAAT	TCTCTTACTG	2200
TCATGCCATC	CGTAAGATGC	TTTTCTGTGA	CTGGTGAGTA	CTCAACCAAG	2250
TCATTCTGAG	AATAGTGTAT	GCGGCGACCG	AGTTGCTCTT	GCCCGGCGTC	2300
AACACGGGAT	AATACCGCGC	CACATAGCAG	AACTTTAAAA	GTGCTCATCA	2350
TTGGAAAACG	TTCTTCGGGG	CGAAAACTCT	CAAGGATCTT	ACCGCTGTTG	2400
AGATCCAGTT	CGATGTAAAC	CACTCGTGCA	CCCAACTGAT	CTTCAGCATC	2450
TTTTACTTTC	ACCAGCGTTT	CTGGGTGAGC	AAAAACAGGA	AGGCAAAATG	2500
CCGCAAAAAA	GGGAATAAAG	GCGACACGGA	AATGTTGAAT	ACTCATACTC	2550
TTCTTTTTC	AATATTATTG	AAGCAGACAG	TTTTATTGTT	CATGATGATA	2600
TATTTTATATC	TTGTGCAATG	TAACATCAGA	GATTTTGAGA	CACAACGTGG	2650
CTTTGTTGAA	TAAATCGAAC	TTTTGCTGAG	TTGACTCCCC	GCGCGCGATG	2700
GGTCGAATTT	GCTTTTCGAA	AAAAAGCCCG	CTCATTAGGC	GGGCTAAAAA	2750
AAAGCCCGCT	CATTAGGCGG	GCTCGAATTT	CTGCCATTCA	TCCGCTTATT	2800
ATCACTTATT	CAGGCGTAGC	AACCAGGCGT	TTAAGGGCAC	CAATAACTGC	2850
CTTAAAAAAA	TTACGCCCCG	CCCTGCCACT	CATCGCAGTA	CTGTTGTAAT	2900
TCATTAAAGCA	TTCTGCCGAC	ATGGAAGCCA	TCACAGACGG	CATGATGAAC	2950
CTGAATCGCC	AGCGGCATCA	GCACCTTGTC	GCCTTGCGTA	TAATATTTGC	3000
CCATAGTGAA	AACGGGGGCG	AAGAAAGTTGT	CCATATTCGC	CACGTTTTAA	3050
TCAAAACTGG	TGAAACTCAC	CCAGGGATTG	GCTGAGACGA	AAAACATATT	3100
CTCAATAAAC	CCTTTAGGGA	AATAGGCCAG	GTTTTTCA	TAACACGCCA	3150
CATCTTGCGA	ATATATGTGT	AGAAACTGCC	GGAAATCGTC	GTGGTATTCA	3200
CTCCAGAGCG	ATGAAAACGT	TTCAGTTTGC	TCATGGAAAA	CGGTGTAACA	3250
AGGGTGAACA	CTATCCCAT	TCACCAGCTC	ACCGTCTTTC	ATTGCCATAC	3300
GAAATTCCGG	ATGAGCATTC	ATCAGGCGGG	CAAGAATGTG	AATAAAGGCC	3350
GGATAAAACT	TGTGCTTATT	TTTCTTTACG	GTCTTTAAAA	AGGCCGTAAT	3400
ATCCAGCTGA	ACGGTCTGGT	TATAGGTACA	TTGAGCAACT	GACTGAAATG	3450

CCTCAAAATG	TTCTTTACGA	TGCCATTGGG	ATATATCAAC	GGTGGTATAT	3500
CCAGTGATTT	TTTTCTCCAT	TTAGCTTCC	TTAGCTCCTG	AAAATCTCGA	3550
TAACTCAAAA	AATACGCCCC	GTAGTGATCT	TATTTTCATTA	TGGTGAAAAGT	3600
TGGAACCTCT	TACGTGCCGA	TCAACGTCTC	ATTTTTCGCCA	AAAGTTGGCC	3650
CAGGGCTTCC	CGGTATCAAC	AGGGACACCA	GGATTTATTT	ATTCTGCGAA	3700
GTGATCTTCC	GTCACAGGTA	TTTATTCGAA	GACGAAAGGG	CATCGCGCGC	3750
GGGGAATTCC	AGCTCGAGCT	TACTCCCCAT	CCCCCTGTTG	ACAATTAATC	3800
ATCGGCTCGT	ATAATGTGTG	GAATTGTGAG	CGGATAACAA	TTTCACACAG	3850
GAAACAGGAT	CCGCGGATCC	GTGGAGAAAA	TAAAATGAAA	CAAAGCACTA	3900
TTGCACTGGC	ACTCTTACCG	TTACTGTTTA	CCCCTGTGAC	AAAAGCGGTA	3950
CCCGGGGATC	CTCTAGAGTC	GACCTGCAGG	CATGCAAGCT	TGGTCTAGAG	4000
GTCGA					4005

4. Sequence Description : SEQ ID NO. 3

SEQUENCE TYPE: DNA sequence of a plasmid, pTE4
SEQUENCE LENGTH: 7049 bp

STRANDEDNESS: double stranded

TOPOLOGY: circular

MOLECULAR TYPE: plasmid DNA replicable in E.coli

FEATURES: - nucleotide (nt) 1 - nt 191 : pUC18 with a 242 bp NdeI-BamHI deletion
- nt 192 to nt 681 : Pnos
- nt 682 - nt 2490 : gus coding sequence
- nt 2491 - nt 2792 : 3'nos
- nt 2793 - nt 3637 : 35S promoter
- nt 3638 - nt 3973 : barnase coding sequence
- nt 3974 - nt 4802 : 3'ocs
- nt 4803 - end : pUC18

PROPERTIES: pTE4 can be used for electroporation of plant cells to evaluate the transient expression of the Pnos-gus-3'ocs and 35S-barnase-3'ocs chimaeric genes. The cytotoxic effect of the barnase gene can be monitored by the expression of GUS.

TCGCGCGTTT	CGGTGATGAC	GGTGAAAACC	TCTGACACAT	GCAGCTCCCG	50
GAGACGGTCA	CAGCTTGTC	GTAAGCGGAT	GCCGGGAGCA	GACAAGCCCG	100
TCAGGGCGCG	TCAGCGGGTG	TTGGCGGGTG	TCGGGGCTGG	CTTAAGTATG	150
CGGCATCAGA	GCAGATTGTA	CTGAGAGTGC	ACCATAGATC	CGTCAATTCC	200
GATTCATTAA	TGCAGCTGGC	ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	250
GTGAGCGCAA	CGCAATTAA	GTGAGTTAGC	TCACTCATTA	GGCACCCAG	300
GCTTTACACT	TTATGCTTCC	GGCTCGTATA	ATGTGTGGAA	TTGTGAGCGG	350
ATAACAATTT	CACACAGGAA	ACAGGATCAT	GAGCGGAGAA	TTAAGGGAGT	400
CACGTTATGA	CCCCCGCCGA	TGACGCGGGA	CAAGCCGTTT	TACGTTTGGA	450
ACTGACAGAA	CCGCAACGAT	TGAAGGAGCC	ACTCAGCCGC	GGGTTTCTGG	500
AGTTTAATGA	GCTAAGCACA	TACGTCAGAA	ACCATTATTG	CGCGTTCAAA	550
AGTCGCCTAA	GGTCACTATC	AGCTAGCAAA	TATTTCTTGT	CAAAAATGCT	600
CCACTGACGT	TCCATAAATT	CCCCTCGGTA	TCCAATTAGA	GTCTCATATT	650
CACTCTCAAT	CAAAGATCCG	GCCCATGATC	CATGGTCCGT	CCTGTAGAAA	700
CCCCAACCCG	TGAAATCAAA	AAACTCGACG	GCCTGTGGGC	ATTCAGTCTG	750
GATCGCGAAA	ACTGTGGAAT	TGATCAGCGT	TGGTGGGAAA	GCGCGTTACA	800
AGAAAGCCGG	GCAATTGCTG	TGCCAGGCAG	TTTTAACGAT	CAGTTCGCCG	850
ATGCAGATAT	TCGTAATTAT	GCGGGCAACG	TCTGGTATCA	GCGCGAAGTC	900
TTTATACCGA	AAGGTTGGGC	AGGCCAGCGT	ATCGTGCTGC	GTTTCGATGC	950
GGTCACTCAT	TACGGCAAAG	TGTGGGTCAA	TAATCAGGAA	GTGATGGAGC	1000
ATCAGGGCGG	CTATACGCCA	TTTGAAGCCG	ATGTCACGCC	GTATGTTATT	1050
GCCGGGAAAA	GTGTACGTAT	CACCGTTTGT	GTGAACAACG	AACTGAACTG	1100
GCAGACTATC	CCGCCGGGAA	TGGTGATTAC	CGACGAAAAC	GGCAAGAAAA	1150
AGCAGTCTTA	CTTCCATGAT	TTCTTTAACT	ATGCCGGAAT	CCATCGCAGC	1200
GTAATGCTCT	ACACCACGCC	GAACACCTGG	GTGGACGATA	TCACCGTGTT	1250

GACGCATGTC	GCGCAAGACT	GTAACCACGC	GTCTGTTGAC	TGGCAGGTGG	1300
TGGCCAATGG	TGATGTCAGC	GTTGAACTGC	GTGATGCGGA	TCAACAGGTG	1350
GTTGCAACTG	GACAAGGCAC	TAGCGGGACT	TTGCAAGTGG	TGAATCCGCA	1400
CCTCTGGCAA	CCGGGTGAAG	GTTATCTCTA	TGAACTGTGC	GTCACAGCCA	1450
AAAGCCAGAC	AGAGTGTGAT	ATCTACCCGC	TTCCGCTCGG	CATCCGGTCA	1500
GTGGCAGTGA	AGGGCGAACA	GTTCTTGATT	AACCACAAAC	CGTTCTACTT	1550
TACTGGCTTT	GGTCGTCATG	AAGATGCGGA	CTTACGTGGC	AAAGGATTCTG	1600
ATAACGTGCT	GATGGTGCAC	GACCACGCAT	TAATGGACTG	GATTGGGGCC	1650
AACTCCTACC	GTACCTCGCA	TTACCCTTAC	GCTGAAGAGA	TGCTCGACTG	1700
GGCAGATGAA	CATGGCATCG	TGGTGATTGA	TGAAACTGCT	GCTGTCGGCT	1750
TTAACCTCTC	TTTAGGCATT	GGTTTCGAAG	CGGGCAACAA	GCCGAAAGAA	1800
CTGTACAGCG	AAGAGGCAGT	CAACGGGGAA	ACTCAGCAAG	CGCACTTACA	1850
GGCGATTAAA	GAGCTGATAG	CGCGTGACAA	AAACCACCCA	AGCGTGGTGA	1900
TGTGGAGTAT	TGCCAACGAA	CCGGATACCC	GTCCGCAAGT	GCACGGGAAT	1950
ATTTCCGCCA	TGGCGGAAGC	AACGCGTAAA	CTCGACCCGA	CGCGTCCGAT	2000
CACCTGCGTC	AATGTAATGT	TCTGCGACGC	TCACACCGAT	ACCATCAGCG	2050
ATCTCTTTGA	TGTGCTGTGC	CTGAACCGTT	ATTACGGATG	GTATGTCCAA	2100
AGCGGCGATT	TGGAAACGGC	AGAGAAGGTA	CTGGAAAAAG	AACTTCTGGC	2150
CTGGCAGGAG	AAACTGCATC	AGCCGATTAT	CATCACCGAA	TACGGCGTGG	2200
ATACGTTAGC	CGGGCTGCAC	TCAATGTACA	CCGACATGTG	GAGTGAAGAG	2250
TATCAGTGTG	CATGGCTGGA	TATGTATCAC	CGCGTCTTTG	ATCGCGTCAG	2300
CGCCGTCGTC	GGTGAACAGG	TATGGAATTT	CGCCGATTTT	GCGACCTCGC	2350
AAGGCATATT	GCGCGTTGGC	GGTAACAAGA	AAGGGATCTT	CACTCGGCAC	2400
CGCAAACCGA	AGTCGGCGGC	TTTTCTGCTG	CAAAAACGCT	GGACTCGCAT	2450
GAACTTCGGT	GAAAAACCGC	AGCAGGGAGG	CAACAATGA	XXXXXXGAAT	2500
TGATCCGAAG	CAGATCGTTC	AAACATTTGG	CAATAAAGTT	TCTTAAGATT	2550
GAATCCTGTT	GCCGGTCTTG	CGATGATTAT	CATATAATTT	CTGTTGAATT	2600
ACGTTAAGCA	TGTAATAATT	AACATGTAAT	GCATGACGTT	ATTTATGAGA	2650
TGGGTTTTTA	TGATTAGAGT	CCCGCAATTA	TACATTTAAT	ACGCGATAGA	2700
AAACAAAATA	TAGCGCGCAA	ACTAGGATAA	ATTATCGCGC	GCGGTGTCTAT	2750
CTATGTTACT	AGATCGGGAA	GATCCTCTAG	AGTCGACCTG	CAGGCATGCA	2800
AGCTCCTACG	CAGCAGGTCT	CATCAAGACG	ATCTACCCGA	GTAACAATCT	2850
CCAGGAGATC	AAATACCTTC	CCAAGAAGGT	TAAAGATGCA	GTCAAAAGAT	2900
TCAGGACTAA	TTGCATCAAG	AACACAGAGA	AAGACATATT	TCTCAAGATC	2950
AGAAGTACTA	TTCCAGTATG	GACGATTCAA	GGCTTGCTTC	ATAAACCAAG	3000
GCAAGTAATA	GAGATTGGAG	TCTCTAAAAA	GGTAGTTCCT	ACTGAATCTA	3050
AGGCCATGCA	TGGAGTCTAA	GATTCAAATC	GAGGATCTAA	CAGAACTCGC	3100
CGTGAAGACT	GGCGAACAGT	TCATACAGAG	TCTTTTACGA	CTCAATGACA	3150
AGAAGAAAAT	CTTCGTCAAC	ATGGTGGAGC	ACGACACTCT	GGTCTACTCC	3200
AAAAATGTCA	AAGATACAGT	CTCAGAAGAC	CAAAGGGCTA	TTGAGACTTT	3250
TCAACAAAGG	ATAATTTCCG	GAAACCTCCT	CGGATTCCAT	TGCCCAGCTA	3300
TCTGTCACTT	CATCGAAAGG	ACAGTAGAAA	AGGAAGGTGG	CTCCTACAAA	3350
TGCCATCATT	GCGATAAAGG	AAAGGCTATC	ATTCAAGATG	CCTCTGCCGA	3400
CAGTGGTCCC	AAAGATGGAC	CCCCACCCAC	GAGGAGCATC	GTGGAAAAAG	3450
AAGACGTTCC	AACCACGTCT	TCAAAGCAAG	TGGATTGATG	TGACATCTCC	3500
ACTGACGTAA	GGGATGACGC	ACAATCCCAC	TATCCTTCGC	AAGACCTTTC	3550
CTCTATATCA	GGAAGTTCAT	TTCATTTGGA	GAGGACACGC	TGAAATCACC	3600
AGTCTCTCTC	TATAAATCTA	TCTCTCTCTC	TATAACCATG	GTACCGGTTA	3650
TCAACACGTT	TGACGGGGTT	GCGGATTATC	TTCAGACATA	TCATAAGCTA	3700
CCTGATAATT	ACATTACAAA	ATCAGAAGCA	CAAGCCCTCG	GCTGGGTGGC	3750

ATCAAAAGGG	AACCTTGCAG	ACGTCGCTCC	GGGGAAAAGC	ATCGGCGGAG	3800
ACATCTTCTC	AAACAGGGAA	GGCAAACCTCC	CGGGCAAAAG	CGGACGAACA	3850
TGGCGTGAAG	CGGATATTAA	CTATACATCA	GGCTTCAGAA	ATTCAGACCG	3900
GATTCTTTAC	TCAAGCGACT	GGCTGATTTA	CAAAACAACG	GACCATTATC	3950
AGACCTTTAC	AAAAATCAGA	TAACGAAAAA	AACGGCTTCC	TGCGGAGGCC	4000
GTTTTTTTCA	GCTTTACATA	AAGTGTGTAA	TAAATTTTTT	TTCAAACCTC	4050
GATCGGTCAA	TTTCACTTTC	CGGXXXXTCT	TAGAGTCCTG	CTTTAATGAG	4100
ATATGCGAGA	CGCCTATGAT	CGCATGATAT	TTGCTTTTCAA	TTCTGTTGTG	4150
CACGTTGTAA	AAAACCTGAG	CATGTGTAGC	TCAGATCCTT	ACCGCCGGTT	4200
TCGGTTCATT	CTAATGAATA	TATCACCCGT	TACTATCGTA	TTTTTATGAA	4250
TAATATTCTC	CGTTCAATTT	ACTGATTGTA	CCCTACTACT	TATATGTACA	4300
ATATTAAAAT	GAAAACAATA	TATTGTGCTG	AATAGGTTTA	TAGCGACATC	4350
TATGATAGAG	CGCCACAATA	ACAAAACAATT	GCGTTTTTATT	ATTACAAATC	4400
CAATTTTAAA	AAAAGCGGCA	GAACCGGTCA	AACCTAAAAG	ACTGATTACA	4450
TAAATCTTAT	TCAAATTTCA	AAAGGCCCCA	GGGGCTAGTA	TCTACGACAC	4500
ACCGAGCGGC	GAACATAATA	CGTTCACTGA	AGGGAACTCC	GGTCCCCCGC	4550
CGGCGCGCAT	GGGTGAGATT	CCTTGAAGTT	GAGTATTGGC	CGTCCGCTCT	4600
ACCGAAAGTT	ACGGGCACCA	TTCAACCCGG	TCCAGCACGG	CGGCCGGGTA	4650
ACCGACTTGC	TGCCCCGAGA	ATTATGCAGC	ATTTTTTTTGG	TGTATGTGGG	4700
CCCCAAATGA	AGTGCAGGTC	AAACCTTGAC	AGTGACGACA	AATCGTTGGG	4750
CGGGTCCAGG	GCGAATTTTG	CGACAACATG	TCGAGGCTCA	GCAGGACCTG	4800
CAGGCATGCA	AGCTTGCGGT	AATCATGGTC	ATAGCTGTTT	CCTGTGTGAA	4850
ATTGTTATCC	GCTCACAAAT	CCACACAACA	TACGAGCCGG	AAGCATAAAG	4900
TGTAAAGCCT	GGGGTGCCTA	ATGAGTGAGC	TAACTCACAT	TAATTGCGTT	4950
GCGCTCACTG	CCCGCTTTCC	AGTCGGGAAA	CCTGTCTGTC	CAGCTGCATT	5000
AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	GTTTGCGTAT	TGGGCGCTCT	5050
TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	TCGGTCTGTT	GGCTGCGGCG	5100
AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	ACGGTTATCC	ACAGAATCAG	5150
GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	AAGGCCAGCA	AAAGCCAGG	5200
AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	TTCCATAGGC	TCCGCCCCCC	5250
TGACGAGCAT	CACAAAAATC	GACGCTCAAG	TCAGAGGTGG	CGAAACCCGA	5300
CAGGACTATA	AAGATACCAG	GCGTTTTCCC	CTGGAAGCTC	CCTCGTGCGC	5350
TCTCCTGTTC	CGACCCTGCC	GCTTACCGGA	TACCTGTCCG	CCTTTCTCCC	5400
TTCCGGGAAGC	GTGGCGCTTT	CTCAATGCTC	ACGCTGTAGG	TATCTCAGTT	5450
CGGTGTAGGT	CGTTCGCTCC	AAGCTGGGCT	GTGTGCACGA	ACCCCCCGTT	5500
CAGCCCGACC	GCTGCGCCTT	ATCCGGTAAC	TATCGTCTTG	AGTCCAACCC	5550
GGTAAGACAC	GACTTATCGC	CACTGGCAGC	AGCCACTGGT	AACAGGATTA	5600
GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	AGTTCTTGAA	GTGGTGCCCT	5650
AACTACGGCT	ACACTAGAAG	GACAGTATTT	GGTATCTGCG	CTCTGCTGAA	5700
GCCAGTTACC	TTCCGAAAAA	GAGTTGGTAG	CTCTTGATCC	GGCAACAAA	5750
CCACCGCTGG	TAGCGGTGGT	TTTTTTGTTT	GCAAGCAGCA	GATTACGCGC	5800
AGAAAAAAG	GATCTCAAGA	AGATCCTTTG	ATCTTTTCTA	CGGGGTCTGA	5850
CGCTCAGTGG	AACGAAAAC	CACGTTAAGG	GATTTTGGTC	ATGAGATTAT	5900
CAAAAAGGAT	CTTCACCTAG	ATCCTTTTAA	ATTAAAAATG	AAGTTTAAA	5950
TCAATCTAAA	GTATATATGA	GTAAACTTGG	TCTGACAGTT	ACCAATGCTT	6000
AATCAGTGAG	GCACCTATCT	CAGCGATCTG	TCTATTTCTG	TCATCCATAG	6050
TTGCTGACT	CCCCGTCTGT	TAGATAACTA	CGATACGGGA	GGGCTTACCA	6100
TCTGGCCCCA	GTGCTGCAAT	GATACCGCGA	GACCCACGCT	CACCGGCTCC	6150
AGATTTATCA	GCAATAAACC	AGCCAGCCGG	AAGGGCCGAG	CGCAGAAGTG	6200
GTCTTGCAAC	TTTATCCGCC	TCCATCCAGT	CTATTAATTG	TTGCCGGGAA	6250

GCTAGAGTAA	GTAGTTCGCC	AGTTAATAGT	TTGCGCAACG	TTGTTGCCAT	6300
TGCTACAGGC	ATCGTGGTGT	CACGCTCGTC	GTTTGGTATG	GCTTCATTCA	6350
GCTCCGGTTC	CCAACGATCA	AGGCGAGTTA	CATGATCCCC	CATGTTGTGC	6400
AAAAAAGCGG	TTAGCTCCTT	CGGTCCTCCG	ATCGTTGTCA	GAAGTAAGTT	6450
GGCCGCAGTG	TTATCACTCA	TGGTTATGGC	AGCACTGCAT	AATTCTCTTA	6500
CTGTCATGCC	ATCCGTAAGA	TGCTTTTCTG	TGACTGGTGA	GTACTIONACC	6550
AAGTCATTCT	GAGAATAGTG	TATGCGGCGA	CCGAGTTGCT	CTTGCCCGGC	6600
GTCAATACGG	GATAATACCG	CGCCACATAG	CAGAACTTTA	AAAGTGCTCA	6650
TCATTGGAAA	ACGTTCTTCG	GGGCGAAAAC	TCTCAAGGAT	CTTACCGCTG	6700
TTGAGATCCA	GTTTCGATGTA	ACCCACTCGT	GCACCCAACT	GATCTTCAGC	6750
ATCTTTTACT	TTCAACGCGG	TTTCTGGGTG	AGCAAAAACA	GGAAGGCAAA	6800
ATGCCGCAAA	AAAGGGAATA	AGGGCGACAC	GGAAATGTTG	AATACTCATA	6850
CTCTTCCTTT	TTCAATATTA	TTGAAGCATT	TATCAGGGTT	ATTGTCTCAT	6900
GAGCGGATAC	ATATTTGAAT	GTATTTAGAA	AAATAAACAA	ATAGGGGTTC	6950
CGCGCACATT	TCCCCGAAAA	GTGCCACCTG	ACGTCTAAGA	AACCATTATT	7000
ATCATGACAT	TAACCTATAA	AAATAGGCGT	ATCACGAGGC	CCTTTCGTC	7049

CLAIMS

1. A method of significantly disrupting the metabolism, functioning and/or development of selected cells, especially cells of a selected tissue and/or organ, of an eucaryotic organism, particularly a plant, by inserting into each cell of said organism, preferably by stably integrating into the nuclear genome of each cell of said organism, a first chimaeric gene comprising:

- i) a Rnase DNA coding for a protein which has Rnase activity and which contains only one intramolecular disulfide bridge; said Rnase DNA preferably being a sarnase DNA, particularly an R08/26 sarnase DNA; and
- ii) a first promoter capable of directing the expression of said Rnase DNA substantially only in said selected cells of said organism; said Rnase DNA being in the same transcriptional unit as, and under the control of, said first promoter.

2. The method of claim 1 in which said Rnase DNA is obtainable from a Streptomyces aureofaciens, preferably strain R08/26, particularly the Rnase DNA which has the nucleotide sequence of SEQ ID no. 1 or codes for the Rnase with the amino acid sequence of SEQ ID no. 1.

3. The method of claim 1 or 2 in which said organism is a plant and in which said first promoter is capable of directing expression of said Rnase DNA selectively in the cells of a male reproductive organ of said plant, particularly the anther, pollen or filament cells, quite particularly in the anther epidermal cells or tapetum cells, or in which said

promoter is capable of directing expression of said RNase DNA selectively in the cells of a female reproductive organs or of seeds or of embryos of said plant, particularly in style, stigma, ovule, septum, seed coat, endosperm, embryo axis or embryo cotyledon cells.

4. The method of claim 1 or 2 in which said organism is a plant and said first promoter is induced by the presence of a nematode, particularly in plant cells of fixed feeding sites.

5. A method to prevent or diminish the disruption of normal metabolism, functioning or development of selected cells of a eucaryotic organism, particularly a plant, containing in each of its cells the first chimaeric gene of any one of claims 1 to 4, by inserting into each cell of said organism, preferably by stably integrating into the nuclear genome of each cell of said organism, a second chimaeric gene comprising:

- i) a RNase-inhibitor DNA coding for a protein that inhibits the RNase activity encoded by the first chimaeric gene; said RNase-inhibitor DNA preferably being a sarstar DNA, particularly a R08/26 sarstar DNA; and
- ii) a second promoter capable of directing the expression of said RNase DNA at least in said selected cells of said organism; said RNase-inhibitor DNA being in the same transcriptional unit as, and under the control of, said second promoter.

6. The method of claim 5 in which said RNase-inhibitor DNA

is obtainable from a S. aureofaciens, preferably strain R08/26

7. The method of claim 5 or 6 in which: said organism is a plant; said first promoter is the promoter of claim 3; and said second promoter is the same as said first promoter or is a constitutive promoter, such as a 35S promoter.

8. A method to produce hybrid seed comprising crossing a plant of a species containing, in each of its cells, said first chimaeric gene of claim 3 with a non-transformed plant of said species or with a plant of said species containing, in each of its cells, said second chimaeric gene of claim 7.

9. A cell of an eucaryotic organism, particularly a plant, the nuclear genome of which is transformed with said first chimaeric gene, said second chimaeric gene, or both of any one of claims 1 to 7.

10. A plant or plant cell culture consisting essentially of the cells of claim 9.

11. A seed of the plant of claim 10.

12. A R08/26 sarnase DNA that is obtainable from Streptomyces aureofaciens strain R08/26 (DSM 6691) and that preferably has the nucleotide sequence of SEQ ID no. 1 or codes for the RNase with the amino acid sequence of SEQ ID no. 1.

13. A R08/26 sarnase, preferably having the amino acid sequence of SEQ ID no. 1.

14. A R08/26 sarstar DNA that is obtainable from Streptomyces aureofaciens strain R08/26 (DSM 6691)


and codes for a protein that is capable of inhibiting the RNase activity of the R08/26 sarnase of claim 13.

15. A R08/26 sarstar that is obtainable from Streptomyces aureofaciens strain R08/26 and is capable of inhibiting the Rnase activity of the R08/26 sarnase of claim 13.

16. A plasmid, such as a Ti-plasmid, comprising said first chimaeric gene of any one of claims 1 to 4 or said second chimaeric gene of any one of claims 5 to 7.

17. The Streptomyces aureofaciens strain R08/26 (DSM 6691).

Figure 1



2/2




Figure 2

INTERNATIONAL SEARCH REPORT

PCT/EP 92/02420

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N15/82; A01N63/02;	C12N15/55; C12N5/10;	C12N9/22; A01H5/00; C12N15/31 A01H1/02
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; A01N ; A01H ; C07K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	BIOTECHNOL. LETT. vol. 13, no. 7, 1991, pages 471 - 476 GODANY, A., ET AL. 'Streptomyces aureofaciens strains as hosts for cloning of genes affecting antibiotic production' see page 472, line 12 - line 20 ---	17
A	EP,A,0 344 029 (PLANT GENETIC SYSTEMS) 29 November 1989 see the whole document ---	1-3, 8-11,16
A	EP,A,0 412 006 (PLANT GENETIC SYSTEMS) 6 February 1991 see the whole document ---	1-3, 8-11,16
A	EP,A,0 412 911 (PLANT GENETIC SYSTEMS) 13 February 1991 see the whole document ---	5-11,16
		-/--
¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 11 FEBRUARY 1993		Date of Mailing of this International Search Report 26.02.93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer MADDOX A.D.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claims No.
A	<p>FEBS LETTERS. vol. 209, no. 2, December 1986, AMSTERDAM NL pages 335 - 339 SHLYAPNIKOV, S. V., ET AL. 'Amino acid sequence determination of guanyl-specific ribonuclease Sa from Streptomyces aureofaciens' see the whole document</p>	2, 12, 13
A	<p>BIOLOGICAL ABSTRACTS vol. 91 , 1991, Philadelphia, PA, US; abstract no. 123121, KRAJCIKOVA, D., ET AL. 'RNase Sa inhibitor from Streptomyces aureofaciens' see abstract & BIOLOGIA (BRATISL.) vol. 45, no. 12, 1990, pages 977 - 986</p>	6, 14, 15
A	<p>CHEMICAL ABSTRACTS, vol. 100, 1984, Columbus, Ohio, US; abstract no. 152940, MUCHA, J., ET AL. 'Ribonuclease inhibitor from Streptomyces aureofaciens. I. Purification and properties' page 227 ; see abstract & BIOLOGIA(BRATISLAVA) vol. 38, no. 12, 1983, pages 1177 - 1184</p>	6, 14, 15
A	<p>TRENDS IN BIOCHEMICAL SCIENCES vol. 14, no. 11, November 1989, pages 450 - 454 HARTLEY, R.W. 'Barnase and barstar: two small proteins to fold and fit together' see page 453, column 2 - column 3</p>	12-15

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9202420
SA 66202

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11/02/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0344029	29-11-89	AU-B-	621113	05-03-92
		AU-A-	3537189	24-11-89
		WO-A-	8910396	02-11-89
		JP-T-	2503988	22-11-90

EP-A-0412006	06-02-91	AU-A-	6273390	11-03-91
		WO-A-	9102068	21-02-91

EP-A-0412911	13-02-91	AU-B-	625509	16-07-92
		AU-A-	6068890	11-03-91
		WO-A-	9102069	21-02-91
		JP-T-	3503004	11-07-91
